Cue Biopharma Valuation
| CUE Stock | USD 1.02 0.01 0.97% |
Today, the firm appears to be undervalued. Cue Biopharma shows a prevailing Real Value of $3.23 per share. The current price of the firm is $1.02. Our model approximates the value of Cue Biopharma from analyzing the firm fundamentals such as operating margin of (3.91) %, and Return On Equity of -1.39 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cue Biopharma's valuation include:
Price Book 2.5474 | Enterprise Value 41.7 M | Enterprise Value Ebitda (1.76) | Price Sales 7.7899 | Enterprise Value Revenue 4.3757 |
Undervalued
Today
Please note that Cue Biopharma's price fluctuation is dangerous at this time. Calculation of the real value of Cue Biopharma is based on 3 months time horizon. Increasing Cue Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cue stock is determined by what a typical buyer is willing to pay for full or partial control of Cue Biopharma. Since Cue Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cue Stock. However, Cue Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.02 | Real 3.23 | Target 10.0 | Hype 0.85 | Naive 0.79 |
The real value of Cue Stock, also known as its intrinsic value, is the underlying worth of Cue Biopharma Company, which is reflected in its stock price. It is based on Cue Biopharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cue Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cue Biopharma helps investors to forecast how Cue stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cue Biopharma more accurately as focusing exclusively on Cue Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cue Biopharma's intrinsic value based on its ongoing forecasts of Cue Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cue Biopharma's closest peers. If more than one evaluation category is relevant for Cue Biopharma we suggest using both methods to arrive at a better estimate.
Cue Biopharma Cash |
|
Cue Valuation Trend
Comparing Cue Biopharma's enterprise value against its market capitalization is a good way to estimate the value of Cue Biopharma uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Cue Biopharma Total Value Analysis
Cue Biopharma is currently anticipated to have company total value of 41.71 M with market capitalization of 64.62 M, debt of 14.7 M, and cash on hands of 66.13 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Cue Biopharma fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
41.71 M | 64.62 M | 14.7 M | 66.13 M |
Cue Biopharma Investor Information
About 24.0% of the company shares are held by institutions such as insurance companies. The book value of Cue Biopharma was currently reported as 0.79. The company recorded a loss per share of 0.91. Cue Biopharma had not issued any dividends in recent years. Based on the key measurements obtained from Cue Biopharma's financial statements, Cue Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Cue Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cue Biopharma has an asset utilization ratio of 8.92 percent. This indicates that the Company is making $0.0892 for each dollar of assets. An increasing asset utilization means that Cue Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Cue Biopharma Ownership Allocation
Cue Biopharma holds a total of 63.35 Million outstanding shares. Almost 75.87 percent of Cue Biopharma outstanding shares are held by general public with 0.54 (percent) owned by insiders and only 23.59 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cue Biopharma Profitability Analysis
The company reported the last year's revenue of 5.49 M. Reported Net Loss for the year was (50.73 M) with profit before taxes, overhead, and interest of 1.25 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cue Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cue Biopharma and how it compares across the competition.
About Cue Biopharma Valuation
The stock valuation mechanism determines Cue Biopharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Cue Biopharma. We calculate exposure to Cue Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cue Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -32.6 M | -31 M | |
| Pretax Profit Margin | (9.24) | (9.70) | |
| Operating Profit Margin | (9.50) | (9.97) | |
| Net Loss | (9.24) | (9.70) | |
| Gross Profit Margin | (5.94) | (6.24) |
Cue Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cue Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 45.8 M |
Cue Biopharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Cue Biopharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cue we look at many different elements of the entity such as Cue's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cue Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cue Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cue Biopharma's worth.Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |